Nom du produit:4-(4-Nitrophenyl)piperidine

IUPAC Name:4-(4-nitrophenyl)piperidine

CAS:26905-03-3
Formule moléculaire:C11H14N2O2
Pureté:95%+
Numéro de catalogue:CM275089
Poids moléculaire:206.25

Unité d'emballage Stock disponible Prix($) Quantité
CM275089-250mg in stock ũȡ
CM275089-1g in stock ƿȡǶ
CM275089-5g 1-2 Weeks ŵũȐ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:26905-03-3
Formule moléculaire:C11H14N2O2
Point de fusion:-
Code SMILES:O=[N+](C1=CC=C(C2CCNCC2)C=C1)[O-]
Densité:
Numéro de catalogue:CM275089
Poids moléculaire:206.25
Point d'ébullition:
N° Mdl:MFCD06804549
Stockage:

Category Infos

Piperidines
Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.
Piperidine,Piperidine Price
if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.

Column Infos

NX-2127
Existing BTK inhibitors directly bind to the active site of BTK and face challenges such as acquired resistance or incomplete responses over time. PROTAC-induced BTK degradation works as a novel alternative therapy for drug-resistant cancers. The latest journal Science publishes the identification of BTK mutations that are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Nurix Therapeutics’ TPD compound NX-2127 is a first-in-class, dual-function small-molecule protein degrader. It drives targeted BTK and transcription factor IKAROS (IKZF1/3) degradation through ubiquitination and proteasomal degradation, adding combined benefit. NX-2127 is under development of phase I clinical trials that shows promising results and a manageable safety profile for the treatment of relapsed/ refractory B-cell malignancies.

Related Products